Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.
HAE Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Haemonetics Corp. To summarize, we found that Haemonetics Corp ranked in the 69th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 188.17% on a DCF basis. As for the metrics that stood out in our discounted cash flow analysis of Haemonetics Corp, consider:
The compound growth rate in the free cash flow of Haemonetics Corp over the past 5.46 years is 0.77%; that's higher than 84.65% of free cash flow generating stocks in the Healthcare sector.
The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately merely 19.64% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
HAE's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 40% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Haemonetics Corp? See HUM, SGRY, ARA, CVS, and PNTG.
BOSTON, Sept. 9, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, Sept. 15, 2020, at 9:30 a.m. ET. The public may access Mr. Simon's…
Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced that it has entered into a definitive agreement to sell its wholly-owned subsidiary Inlog Holdings France SAS to Abénex. Abénex is a fully independent private equity firm based in France. Inlog Holdings France SAS, through its subsidiary In Log SAS, develops and sells blood bank and hospital software solutions used predominantly in France and in several other countries outside of the U.S.
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]